Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
Sponsor: Advenchen Pharmaceuticals, LLC.
Summary
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Official title: A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2022-11-01
Completion Date
2026-12
Last Updated
2025-09-23
Healthy Volunteers
No
Conditions
Interventions
AL8326 low dose group
Taken AL3826 at low dose orally
AL8326 middle dose group
Taken AL3826 at middle dose orally
AL8326 high dose group
Taken AL3826 at high dose orally
Locations (6)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Northwestern University
Chicago, Illinois, United States
Siteman Cancer Center, Washington University
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramón Y Cajal
Madrid, Spain